My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

475.15 -7.30 (-1.51%)

Streaming Delayed Price Updated: 2:26 PM EST, Feb 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Why Madrigal Pharmaceuticals Stock Slumped on Tuesday ↗

January 06, 2026

The stock has had quite the run following Rezdiffra's 2024 approval by the FDA.

Via The Motley Fool

Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead ↗

January 05, 2026

There is a key difference between these two biotechs.

Via The Motley Fool

Topics Bankruptcy

2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026 ↗

January 03, 2026

The pharmaceutical leader looks poised to stop the bleeding.

Via The Motley Fool

2 Predictions for Novo Nordisk in 2026 ↗

December 14, 2025

The company's worst days might be behind it.

Via The Motley Fool

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

2 Stocks Up Over 600% in the Past 3 Years With More Room to Run ↗

December 09, 2025

They haven't peaked yet.

Via The Motley Fool

Topics Intellectual Property

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

December 03, 2025

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 28, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 27, 2025

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

Via The Motley Fool

Topics Lawsuit Regulatory Compliance

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones ↗

November 27, 2025

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Via The Motley Fool

Topics Initial Public Offering Regulatory Compliance

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗

November 27, 2025

Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.

Via The Motley Fool

Topics Regulatory Compliance

Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum ↗

November 24, 2025

Fresh analyst target hikes followed new two-year clinical data showing sustained improvements in key liver-health measures.

Via Stocktwits

Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday ↗

November 20, 2025

Via Benzinga

Expedia, Sandisk and Penumbra Are Among the Top 10 Large-Cap Gainers Last Week (Nov. 3-Nov. 7): Are the Others in Your Portfolio? ↗

November 09, 2025

Expedia, SanDisk, and Penumbra led last week's large-cap gainers, with strong earnings and raised guidance fueling broad double-digit jumps.

Via Benzinga

Madrigal Pharmaceuticals (NASDAQ:MDGL) Q3 2025 Earnings: Revenue Beat and EPS Miss Drive Pre-Market Surge ↗

November 04, 2025

Madrigal's Q3 2025 earnings show Rezdiffra sales of $287.3M, crushing estimates. With over 29,500 patients on therapy, the stock surged on strong commercial uptake.

Via Chartmill

A Look Ahead: Madrigal Pharmaceuticals's Earnings Forecast ↗

November 03, 2025

Via Benzinga

Beyond The Numbers: 10 Analysts Discuss Madrigal Pharmaceuticals Stock ↗

October 15, 2025

Via Benzinga

6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner ↗

September 30, 2025

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.

Via Benzinga

A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 7 Analysts ↗

September 29, 2025

In the latest quarter, 7 analysts provided ratings for Madrigal Pharmaceuticals (NASDAQ: MDGL), showcasing a mix of bullish and bearish perspectives.

Via Benzinga

MADRIGAL PHARMACEUTICALS INC (NASDAQ:MDGL) Screens as High-Growth Momentum Stock Meeting Minervini Trend Template ↗

September 24, 2025

Madrigal Pharmaceuticals (MDGL) meets Mark Minervini's high-growth trend template, showing explosive revenue growth and a perfect 10/10 technical rating.

Via Chartmill

MarketBeat Week in Review – 09/08 - 09/12 ↗

September 13, 2025

Markets had another strong week as inflaton data set the stage for the Federal Reserve’s meeting next week; a rate cut is expected but may already be priced in

Via MarketBeat

Topics Economy

General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday ↗

September 12, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Madrigal Pharmaceuticals Through 6 Analysts ↗

September 12, 2025

Via Benzinga

CoreWeave and Madrigal's Insider Trades Flash Bullish Signals ↗

September 10, 2025

Insider trades at NVIDIA-backed CoreWeave and Madrigal Pharmaceuticals are bullish indicators, but for very different reasons.

Via MarketBeat

Topics Artificial Intelligence

Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure ↗

August 28, 2025

Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment.

Via Investor's Business Daily

Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker ↗

August 26, 2025

HC Wainwright starts Gyre Therapeutics coverage with a Buy rating, citing hydronidone's $6 billion potential and strong fibrosis treatment pipeline.

Via Benzinga

Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

August 26, 2025

Via Benzinga

Corporate Wins: Intel, Palo Alto Networks, and Novo Nordisk Drive Market Optimism

August 20, 2025

In a week marked by a surge of positive corporate news, three industry giants—Intel, Palo Alto Networks, and Novo Nordisk—have delivered significant boosts to investor confidence, signaling robust...

Via MarketMinute

Topics Artificial Intelligence Economy

Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal Pharma ↗

August 18, 2025

The FDA will allow patients with MASH to undergo Wegovy treatment, hampering the only other company with an approved MASH drug.

Via Investor's Business Daily

Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease ↗

August 18, 2025

FDA approves Novo Nordisk's Wegovy for MASH with liver fibrosis, supported by ESSENCE trial data as the company projects lower 2025 sales growth.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.